ICER vs NICE: How the US & UK Assess Drug Value & Price
An in-depth comparison of ICER (US) vs NICE (UK). Explore their methods, QALY thresholds, and how they assess drug value to influence global pricing floors.
Back to Articles
Articles tagged with “cost-effectiveness”
Gene Therapy Pricing: The Economics of Million-Dollar Cures
Updated April 2026: Million-dollar gene therapy pricing analysis covering Casgevy, Lyfgenia, Lenmeldy, Elevidys (with 2025 safety update), the Roctavian and Beqvez market withdrawals, and CMS's 2025 Cell and Gene Therapy Access Model. Compares one-time cure costs to lifetime chronic care using value-based pricing, ICER QALY thresholds, and outcomes-based contracts.
How to Handle Payer Objections in the U.S. Oncology Market: A Comprehensive Guide
Practical guide for Market Access teams and field representatives on handling common payer objections in oncology, including strategies for verbal and written communications, real-world examples, and response frameworks.